Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FER | P16591 | 1/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629301 | 0.88 | CYP1A2 (0.55) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL13629273 | 0.87 | CYP1A2 (0.57) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL13629278 | 0.85 | CYP1A2 (0.45) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL13629291 | 0.84 | CYP1A2 (0.44) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL5094762 | 0.80 | MAPT (0.61) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL518104 | 0.79 | MAPT (0.60) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL518105 | 0.79 | MAPT (0.60) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL29573000 | 0.79 | MAPT (0.60) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL13629287 | 0.76 | CYP1A2 (0.45) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL15985422 | 0.75 | SMN1; SMN2 (0.42) | CYP1A2SMN1; SMN2ALDH1A1GSK3BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-11-26 | — | — | US | disclosed |
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-11-26 | — | — | US | disclosed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2007050383-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050401-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291941-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, RET | CYP1A2 2949/4885SMN1; SMN2 4077/4885ALDH1A1 1303/4885 |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | CYP1A2 4074/4885SMN1; SMN2 3373/4885ALDH1A1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.